Clinical Trials

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05909995 2025-02-18

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

DermatologicGastrointestinalGenitourinary

8 enrolled

Turcot syndrome, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

91 enrolled

Melanoma

NCT04967196 2024-12-10

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

6 enrolled

Melanoma

NCT05169957 2024-11-05

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

2 enrolled

Uveal Melanoma, Melanoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

11 enrolled

Melanoma

NCT03752398 2024-07-05

DUET-3

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

198 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01621490 2024-04-23

PD-1

170 enrolled 34 charts

Melanoma

NCT01738139 2024-03-21

Ipilimumab and Imatinib Mesylate in Advanced Cancer

DermatologicGastrointestinalSarcoma

68 enrolled

Melanoma, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

22 enrolled 14 charts

Melanoma

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

3 enrolled 5 charts

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

73 enrolled

Melanoma

NCT00790010 2023-05-11

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

46 enrolled

Melanoma

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

17 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02307149 2023-01-17

MITCI

50 enrolled

Melanoma

NCT02659540 2022-10-28

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

20 enrolled 15 charts

Melanoma

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

8 enrolled 16 charts

Melanoma, Neoplasms

NCT01838200 2022-10-12

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

5 enrolled 12 charts

Melanoma

NCT02437279 2022-04-15

OpACIN

Phase 1 Unknown

20 enrolled

Melanoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

15 enrolled

Melanoma

NCT02381314 2022-02-08

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

24 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03425461 2021-04-02

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

6 enrolled

Melanoma

NCT01024231 2021-03-22

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

127 enrolled 28 charts

Melanoma

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

22 enrolled

Melanoma

NCT03565406 2020-05-21

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

11 enrolled

Melanoma

NCT02516527 2020-05-01

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

25 enrolled

Melanoma

NCT04274816 2020-02-18

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

13 enrolled

Melanoma

NCT02117362 2019-03-21

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

8 enrolled

Melanoma

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

BreastDermatologicHead & NeckLymphoid

80 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

DermatologicGynecologicMyeloidOther hematologic neoplasmThoracic

26 enrolled

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Melanoma, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01608594 2018-08-28

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

30 enrolled

Melanoma

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

38 enrolled

DermatologicGastrointestinalGenitourinaryHead & Neck

Melanoma

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase 1 Unknown

69 enrolled

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02935790 2017-08-24

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

1 enrolled

Melanoma

NCT02210104 2017-07-21

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Phase 1 Withdrawn

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

19 enrolled

Melanoma, Neoplasm Metastasis

NCT01496807 2017-04-28

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

31 enrolled 11 charts

Melanoma

NCT02406183 2017-01-10

Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

13 enrolled

Melanoma, Radiation Injuries

NCT01984255 2016-12-29

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

3 enrolled

Melanoma

NCT01950195 2016-11-15

SRS (Stereotactic Radiosurgery) Plus Ipilimumab

4 enrolled

Melanoma, Neoplasm Metastasis

NCT01557114 2016-06-09

Mel-Ipi-Rx

19 enrolled

Melanoma

NCT02608437 2015-11-18

NIBIT-M4

Phase 1 Unknown

19 enrolled

Melanoma

NCT01400451 2015-01-01

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

18 enrolled 9 charts